The model demonstrates impressive predictive accuracy, how does it perform in identifying associations for rare or underrepresented diseases? Also, while the model integrates protein-drug affinity and disease similarity, how sensitive is it to variations in input data? Were any robustness tests conducted to evaluate performance across different drug-disease databases, or would model retraining be required for datasets with significantly different distributions?
